INFLUENCE OF ARACHIDONIC-ACID ON INDEXES OF PHOSPHOLIPASE-A(2) ACTIVITY IN THE HUMAN NEUTROPHIL

被引:31
作者
WINKLER, JD
SUNG, CM
HUBBARD, WC
CHILTON, FH
机构
[1] WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT BIOCHEM, WINSTON SALEM, NC 27103 USA
[2] JOHNS HOPKINS UNIV, BALTIMORE, MD 21224 USA
[3] WAKE FOREST UNIV, BOWMAN GRAY SCH MED, PULM & CRIT CARE MED SECT, WINSTON SALEM, NC 27103 USA
关键词
D O I
10.1042/bj2910825
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The present studies were conducted to understand better the regulation of phospholipase A2 (PLA2)-dependent mobilization of lipid mediators by arachidonic acid (C20:4). After stimulation of human neutrophils, g.l.c./m.s. analysis of non-esterified fatty acids indicated that the quantity of C20:4 increased as a function of time after stimulation, from undetectable quantities to > 800 pmol/10(7) cells. In contrast with C20:4, the quantities of other free fatty acids such as oleic and linoleic were high in resting cells and did not change after stimulation. Some 15% of the C20:4 released from cellular lipids remained cell-associated. To examine the effect of C20:4 on its own release, neutrophils were exposed to [H-2(8)C20:4, to differentiate it by g.l.c./m.s. from naturally occurring C20:4. In A23187-stimulated neutrophils, low concentrations (5-10 muM) of [H-2(8)C20:4 added just before A23187 increased the quantity of C20:4 produced by the cell, whereas higher concentrations (30-50 muM) decreased the quantity of C20:4 released from phospholipids. As other measures of PLA2 activity, the effects of C20:4 on production of platelet-activity factor (PAF) and leukotriene B4 (LTB4) were assessed. C20:4 treatment just before stimulation of neutrophils blocked PAF and LTB4 production in a concentration-dependent manner (IC50 10-20 muM). The effect of C20:4 was not blocked by the cyclo-oxygenase inhibitor naproxine (10 muM), nor could it be mimicked by 1 muM LTB4, 5-hydroxyeicosa-6,8,11,14-tetraenoic acid (5HETE), 5-hydroperoxyeicosa-6,8,11,14-tetraenoic acid (5HPETE) or 15-hydroxyeicosa-5,8,11,13-tetraenoic acid (15HETE). The 5-lipoxygenase (5LO) inhibitor zileuton induced a concentration-dependent decrease in PAF, with a maximal effect of a 50% decrease at 10-50 muM. The decrease in PAF by the 5LO inhibitor could not be circumvented by addition of 1 muM 5HETE, 5HPETE and LTB4, and may be attributed to the capacity of zileuton to increase the quantity of C20:4 in A23187-treated neutrophils. The inhibitory effect of C20:4 (20-40 muM) on PAF production could be antagonized by the protein kinase C inhibitor staurosporine (30 nM), but not by inhibitors of protein kinase A, tyrosine kinase or calmodulin kinase II. Taken together, these data demonstrate that C20:4 is selectively released from membrane phospholipids of A23187-stimulated neutrophils, and this C20:4 may play an important role in regulating the mobilization of C20:4 by altering PLA2 activity.
引用
收藏
页码:825 / 831
页数:7
相关论文
共 66 条
[1]  
ABRAMSON SB, 1991, J IMMUNOL, V147, P231
[2]   A CYTOSOLIC PHOSPHOLIPASE IN HUMAN-NEUTROPHILS THAT HYDROLYZES ARACHIDONOYL-CONTAINING PHOSPHATIDYLCHOLINE [J].
ALONSO, F ;
HENSON, PM ;
LESLIE, CC .
BIOCHIMICA ET BIOPHYSICA ACTA, 1986, 878 (02) :273-280
[3]   DIRECT ACTIVATION OF PHOSPHOLIPASE-A2 BY GTP-BINDING PROTEIN IN HUMAN PERIPHERAL POLYMORPHONUCLEAR LEUKOCYTES [J].
ANDO, M ;
FURUI, H ;
SUZUKI, K ;
TAKI, F ;
TAKAGI, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 183 (02) :708-713
[4]   IDENTITY BETWEEN PALMITOYL-COA SYNTHETASE AND ARACHIDONOYL-COA SYNTHETASE IN HUMAN PLATELETS [J].
BAKKEN, AM ;
FARSTAD, M ;
HOLMSEN, H .
BIOCHEMICAL JOURNAL, 1991, 274 :145-152
[5]   INHIBITION OF HUMAN-PLATELET PHOSPHOLIPASE-A2 ACTIVITY BY UNSATURATED FATTY-ACIDS [J].
BALLOU, LR ;
CHEUNG, WY .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (02) :371-375
[6]   ARACHIDONIC-ACID INDUCES PHOSPHORYLATION OF AN 18 KDA PROTEIN IN ELECTRICALLY PERMEABILIZED RAT ISLETS OF LANGERHANS [J].
BASUDEV, H ;
JONES, PM ;
PERSAUD, SJ ;
HOWELL, SL .
FEBS LETTERS, 1992, 296 (01) :69-72
[7]  
BILLAH MM, 1985, J BIOL CHEM, V260, P6899
[8]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[9]  
BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
[10]  
CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929